68Ga-PSMA PET/CT在转移性骨肉瘤评估中优于18F-FDG PET/CT的病例报告
本文报告一例75岁男性胸骨骨肉瘤患者,68Ga-PSMA PET/CT在原发肿瘤和转移灶中显示的放射性示踪剂活性高于18F-FDG PET/CT。该病例提示68Ga-PSMA PET/CT因骨肉瘤在体内表达PSMA而对分期非常有用,并可能对预后及治疗后的反应评估具有潜在影响。PSMA靶向放射性配体治疗可能尤其对转移性化疗难治性骨肉瘤有益。
要点
- 68Ga-PSMA PET/CT在原发和转移性骨肉瘤中示踪剂活性高于18F-FDG PET/CT。
- 骨肉瘤体内表达PSMA,68Ga-PSMA PET/CT对分期非常有用。
- PSMA靶向放射性配体治疗可能对转移性化疗难治性骨肉瘤有益。
核心结论
- 68Ga-PSMA PET/CT因骨肉瘤体内表达PSMA而对分期非常有用。
- 68Ga-PSMA PET/CT可能对骨肉瘤的预后和治疗后反应评估具有潜在影响。
- PSMA靶向放射性配体治疗可能尤其对转移性化疗难治性骨肉瘤有益。
研究设计与样本
- 本文为病例报告,报告一例75岁男性胸骨骨肉瘤患者。
主要发现
- 68Ga-PSMA PET/CT在原发肿瘤和转移灶中显示的放射性示踪剂活性高于18F-FDG PET/CT。
临床怎么用
- 68Ga-PSMA PET/CT可用于骨肉瘤分期评估。
- PSMA靶向放射性配体治疗可考虑用于转移性化疗难治性骨肉瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present the case of a 75-year-old man with osteosarcoma of the sternum in whom 68Ga-prostate-specific membrane antigen (PSMA) PET/CT showed high radiotracer activity in the primary tumor and metastatic lesions than 18F-FDG PET/CT. The present case shows that 68Ga-PSMA PET/CT is very useful for staging of osteosarcoma due to in vivo expression of PSMA. 68Ga-PSMA PET/CT can have potential effects on prognosis and in response assessment following treatment in osteosarcoma. The use of PSMA-targeted radioligand treatments may be beneficial especially in metastatic chemorefractory osteosarcoma.
引用
- Can C, Gündoğan C, Kömek H, et al. Is 68Ga-Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma? Clin Nucl Med. 2021. PMID: 33031232. doi:10.1097/RLU.0000000000003320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。